I get why PATT is so salty
3 month share price performance
Angle = +88%
Shield Therapeutics = -10%
You obviously invested in the wrong company
sent from my iPhone |
Nice one raddersSandy..
The bottom line...
'..In our view, these developments should also help secure new Pharma Services contracts - a key strategic objective for ANGLE - by providing these customers with a sample-to-answer solution that delivers comprehensive molecular insights across many cancers to help guide targeted therapy. Our ANGLE valuation is £155m, equivalent to 48p per share.' |
Wonder when the placing RNS will appear. Any potential deal with Illumina is years away but the bills need paying now. |
Thanks. Doesn't say that much, and £155m could be this yr, assuming Illumina don't just buy us out. |
Trinity Delta valuation £155m, equivalent to 48p per share |
If I have Lung cancer I want a dual test to know the full picture of actionable biomarkers. And so does my Oncologist. And perhaps just as importantly so does the Payer/Insurer. They don't want to spend tens of thousands on the wrong treatment.
This is the first time I have seen a clear path to substantial revenues. AN was clear that they will be co-marketing this and Illumina is just as clear giving prime time to the webinar. The companion diagnostic to trials will also be a revenue earner but still many years away.
The market size for ctDNA analysis I have seen a recent estimate for 2030 revenue of $60 billion. A dual test will take some of that market and Angle are in a unique position.
I really cannot see them at a current £50m market cap being independent in 2 years time. Just my view. |
Are we in the 'eye'.....
Think we may have an interesting couple of months of newsflow. |
jelenko - AN made it clear that they'd been working on this particular dual ctDNA & CTC end to end solution for some six months. The fact that it involves the dual marketing of products through their infrastructure indeed bodes well.
Perhaps worth remembering that this is solely for Lung Cancer & as we know Parsortix has worked on every indication it has been used on.
In addition Angle have the Nuprobe NGS option, perhaps to include those who have yet to commit to Illumina.
Apologies for the preamble & in reply to your point, imho I suspect you are correct, a formal arrangement may well be on the horizon. |
I suspect once more information is conveyed next week relating to this relationship market participants will sit up and take notice - for now this is presenting an opportunity for investors/traders to clamber aboard. |
Goosed, Interesting that. Anne-Sophie Pailhes-Jimenez Is Angle's Head of R&D and referenced in that tweet by @illumina. These companies are working so closely together that a formal closer business relationship must be on the cards |
Taking the recent news flow into account, the Illumina collaboration, marketing & webinar, the seminal part Parsortix has played in revealing and facilitating an entirely novel approach in cancer treatment - it is little wonder that Angle are actively recruiting a bigger headcount. The most recent target being for a European Clinical Trials Director. |
I should well imagine there'd be an attempt at a 'kong-sized' treeshake. |
Weird that there's only 100k max online offer but well inside the spread.
You can buy for mid price for smaller amounts and 100k is 15.44p normally when you can get well inside the spread you can buy size.
So it's hard to tell if it pushes on this morning or drops back atm |
Surely a snippet in the Mail this morning 😆 |
Outsize - exactly. I have heard the sales pitch for CT DNA companies at many a conference stand… And they basically offer the same thing though some have NGS panels that have been verified clinically.
Angle offers them a USP… And a likely marketing tool - ?DNA Complete? DNA 360? Something like that… To sell market to new customers and sell to that enormous base they already have… |
Illumina seem keen : |
Bones, though right 90% of the time over the years, and other nay-sayers, are, imho, missing the BIG implication in today's announcement.
Although a joint venture, we now have maybe x20 times more salespeople pushing this. Illumina are going to PUSH this hard.
You don't give away access to one of your main selling presentations, and then sit back.
The presentation, if well received, which by implication Illumina thinks it will, will turn Angles revenues.J.curved |
I would rather go by what the Co says, and its announcements through RNS rather than listen to someone like you, an anonymous poster on a bulletin board, clearly with axe to grind or trader sowing FUD to get back in lower who was screaming sell at 7.5p.Enjoy the ride up |
Revisit the question in 2nd q. |
Yes I feel it's going to be some time before they see any kind of income from this though but down the line it looks very good . They have to negotiate getting to there yet and will need some cash and revenues to pick up quite a lot to narrow the gap but it's a win as you say.
They raised 9m only a few months before results last year ,I think that money has almost gone and a few quid more as results approach in may,/ June . Hence why I suspect another one will be needed before then . What price it's at depends on news in the next few months . . |
Andrew always likes, sensibly a 6 month window. If they raise, and at what price is at this point, unknown, but after today more likely at a premium than a big discount. That's not for now. Enjoy the wins, and today was a big win |
which was, exactly?
Above post rather proves mine ;¬)
At least it did before it was edited, without indication :¬( |
Above two posts kind of prove my point .
Waterloo no worries from me things change and you have to change with them . Happy to concede the down cycle seems to be coming to an end finally after many years here . Still some obstacles remain but it's picked up at least . Let's hope momentum can be maintained with further deals and a raise at a reasonable price to see them closer to break even . I think the time set for that was early 2026 but that was before the revenue misses last year . Not sure if they have stated a new estimate for breaking even yet. |
thiopia - get with the programme!
bones is a pita and he knows it - part of the cultivated persona. dazzle - appreciate the sentiment, but in my long experience of advfn, I can tell you that all posts telling other posters what they should or should not post are a total waste of time. Including, inevitably, this one :¬(
If you don't like them, filter or ignore, but never, ever, take them seriously ;¬) |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
